Global drug major Cipla Ltd announced on Friday that it had received approval of the United States Food and Drug Administration (USFDA) for its new drug Darifenacin tablets for treating bladder symptoms.
"The generic tablet in 7.5mg and 15 mg (dose) are used for treating overactive bladder with symptoms of urge in urinary incontinence, urgency and frequency," said the city-based company in a statement here.
The new drug is AB-rated generic equivalent of Allergan's Enablex tablets.
The company will launch the product soon.
According to IMS Health, the American firm that provides information, services and technology for the healthcare industry, Enablex tablets and generic equivalents had US sales of $85 million for the 12-month period ending June.
--IANS
fb/vd
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app